Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT38RM1)

• DTT Name: Glycoprotein IIb/IIIa receptor (GPIIb/IIIa) DTT Info
• Gene Name: ITGA2B

Molecule-Related Drug & Molecule List

4 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Abciximab	DMJO6GV	Acute disease		Approved	[1]
Eptifibatide	DMQXTJS	Acute cardiac ischemic events	BA40.Z	Approved	[2]
Hydroquinone	DM6AVR4	Melasma	ED60.1	Approved	[3]
Tirofiban	DMQG17S	Acute coronary syndrome	BA41	Approved	[1]

6 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DMP-444	DMO7BQS	Coronary artery disease	BA80	Phase 3	[4]
99mTc-rBitistatin	DMFAMNH	Pulmonary embolism	JB42	Phase 1/2	[5]
AjvW2	DM6PN4H	Thrombosis	DB61-GB90	Phase 1	[6]
Lefradafiban	DMKZVLH	Angina pectoris	BA40	Phase 1	[7]
RGD-891	DMVJMF1	Thrombosis	DB61-GB90	Phase 1	[8]
SDZ-GPI-562	DMU9ZGN	Thrombosis	DB61-GB90	Phase 1	[9]

28 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LAMIFIBAN	DMHR1A7	Angina pectoris	BA40	Discontinued in Phase 3	[10]
LOTRAFIBAN	DMHE804	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 3	[11]
ORBOFIBAN	DMEDLXJ	Angina pectoris	BA40	Discontinued in Phase 3	[12]
SIBRAFIBAN	DMZU1TV	Angina pectoris	BA40	Discontinued in Phase 3	[13]
XEMILOFIBAN	DMBRYT8	Cardiovascular disease	BA00-BE2Z	Discontinued in Phase 3	[14]
Cromafiban	DMZLIUQ	Coronary artery disease	BA80	Discontinued in Phase 2	[15]
ELAROFIBAN	DM7TM91	Thrombosis	DB61-GB90	Discontinued in Phase 2	[16]
FK-633	DMQ3O4C	Artery stenosis	BD52	Discontinued in Phase 2	[17]
Gantofiban	DMHAM2J	Arteriosclerosis	BD40	Discontinued in Phase 2	[18]
MK-852	DMBJLZG	Thrombosis	DB61-GB90	Discontinued in Phase 2	[15]
SR-121787	DMCEQKG	Thrombosis	DB61-GB90	Discontinued in Phase 2	[19]
YM-337	DMCZIGQ	Angiogenesis disorder	BE2Z	Discontinued in Phase 2	[20]
ZD-2486	DMLFNMB	Angina pectoris	BA40	Discontinued in Phase 2	[15]
DMP-728	DMCK7LM	Thrombosis	DB61-GB90	Discontinued in Phase 1	[21]
FR-158999	DM5FW8Y	Thrombosis	DB61-GB90	Discontinued in Phase 1	[22]
L-734217	DMSB0J8	Thrombosis	DB61-GB90	Discontinued in Phase 1	[23]
ME-3277	DMUMSFR	Thrombosis	DB61-GB90	Discontinued in Phase 1	[24]
SC-52012	DMFC19E	Thrombosis	DB61-GB90	Discontinued in Phase 1	[25]
TAK-029	DMN02XD	Thrombosis	DB61-GB90	Discontinued in Phase 1	[26]
TP-9201	DMCV2KQ	Thrombosis	DB61-GB90	Discontinued in Phase 1	[27]
BIBU-251	DMMNI5K	Thrombosis	DB61-GB90	Terminated	[28]
Fradafiban	DMN4E5H	Thrombosis	DB61-GB90	Terminated	[29]
GR-144053	DMN8TH1	Thrombosis	DB61-GB90	Terminated	[30]
GR-233548	DMHM0EU	Thrombosis	DB61-GB90	Terminated	[1]
L-703014	DM47MKE	Thrombosis	DB61-GB90	Terminated	[31]
SB-208651	DMJD15H	Thrombosis	DB61-GB90	Terminated	[32]
SC-49992	DMY7KHW	Arterial thrombosis	DB61-DD30	Terminated	[33]
SKF-106760	DM7QPYK	Thrombosis	DB61-GB90	Terminated	[1]

3 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RGD	DMFASRB	Discovery agent	N.A.	Investigative	[34]
RGD-039	DM0O9VG	Thrombosis	DB61-GB90	Investigative	[35]
XV454	DML1K07	Discovery agent	N.A.	Investigative	[36]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [2] Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem. 1991 May 25;266(15):9359-62.
• [3] Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis. Blood. 1998 Nov 1;92(9):3268-76.
• [4] Evaluation of Tc-99m-labeled glycoprotein IIb/IIIa receptor antagonist DMP444 SPECT in patients with infective endocarditis. Clin Nucl Med. 2003 Jun;28(6):480-4.
• [5] Platelet binding and biodistribution of [99mTc]rBitistatin in animal species and humans. Nucl Med Biol. 2007 Oct;34(7):855-63.
• [6] Novel approaches to the treatment of thrombosis. Trends Pharmacol Sci. 2002 Jan;23(1):25-32.
• [7] Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplasty. Heart. 2001 Apr;85(4):444-50.
• [8] Pharmacokinetics, pharmacodynamics, and safety of a platelet GPIIb/IIIa antagonist, RGD891, following intravenous administration in healthy male volunteers. J Clin Pharmacol. 2000 Nov;40(11):1245-56.
• [9] Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications. Semin Thromb Hemost. 1999;25 Suppl 1:67-75.
• [10] Lamifiban. Drugs. 1999 Feb;57(2):215-21; discussion 222-3.
• [11] Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker.Expert Opin Investig Drugs.2000 Nov;9(11):2673-87.
• [12] Orbofiban: an orally active GPIIb/IIIa platelet receptor antagonist. Med Res Rev. 2001 May;21(3):211-26.
• [13] Pharmacokinetics and pharmacodynamics of sibrafiban, an orally administered GP IIb/IIIa antagonist, following coadministration of aspirin and heparin. J Clin Pharmacol. 2000 May;40(5):488-95.
• [14] Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist. J Pharmacol Exp Ther. 2000 Nov;295(2):670-6.
• [15] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [16] 1,2,4-triazolo[3,4-a]pyridine as a novel, constrained template for fibrinogen receptor (GPIIb/IIIa) antagonists. Bioorg Med Chem Lett. 2001 Oct 8;11(19):2619-22.
• [17] Efficacy of FK633, an ultra-short acting glycoprotein IIb/IIIa antagonist on platelet preservation during and after cardiopulmonary bypass. Eur J Cardiothorac Surg. 2004 Aug;26(2):289-93.
• [18] Enantioseparation of gantofiban precursors on chiral stationary phases of the poly-(N-acryloyl amino acid derivative)-type. J Pharm Biomed Anal. 2002 Jan 15;27(3-4):627-37.
• [19] Prevention of thrombosis and enhancement of thrombolysis in rabbits by SR 121787, a glycoprotein II/III antagonist. J Pharmacol Exp Ther. 1998 Aug;286(2):670-5.
• [20] Pharmacodynamic characterization of the interaction between the glycoprotein IIb/IIIa inhibitor YM337 and unfractionated heparin and aspirin in hum... Br J Clin Pharmacol. 2003 Sep;56(3):321-6.
• [21] Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GPIIb/IIIa receptor antagonist. Circulation. 1994 Jan;89(1):3-12.
• [22] QSAR study of the peptidic fibrinogen inhibitors FK633, FR158999 and related derivatives, using a novel and useful hydrophobic descriptor (logPmw). Bioorganic & Medicinal Chemistry Letters Volume 8, Issue 18, 22 September 1998, Pages 2483-2488.
• [23] Nonpeptide glycoprotein IIb/IIIa inhibitors. 8. Antiplatelet activity and oral antithrombotic efficacy of L-734,217. J Pharmacol Exp Ther. 1996 Jul;278(1):62-73.
• [24] ME3277, a GPIIb/IIIa antagonist reduces cerebral infarction without enhancing intracranial hemorrhage in photothrombotic occlusion of rabbit middle cerebral artery. J Cereb Blood Flow Metab. 2000 Jun;20(6):988-97.
• [25] Characterization of Binding of an RGD Mimetic, [(3)H]-SC-52012, to Platelet GPIIb/IIIa. Platelets. 1995;6(5):288-95.
• [26] Platelet protective effect of TAK-029, a novel glycoprotein IIb/IIIa antagonist: an in vitro study. Artif Organs. 1998 Apr;22(4):348-52.
• [27] TP-9201, a glycoprotein IIb/IIIa platelet receptor antagonist, prevents rethrombosis after successful arterial thrombolysis in the dog. Stroke. 1997 Sep;28(9):1789-96.
• [28] CN patent application no. 101312747, Anticoagulant antithrombotic dual inhibitors comprising a biotin label.
• [29] Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, Lefradafiban, in men. Circulation. 1997Aug 19;96(4):1130-8.
• [30] GR144053, a fibrinogen receptor antagonist, enhances the suppression of neointima formation by losartan, an angiotensin II receptor antagonist, in ... Br J Pharmacol. 1997 Nov;122(6):1099-104.
• [31] Pharmacokinetics and pharmacodynamics of L-703,014, a potent fibrinogen receptor antagonist, after intravenous and oral administration in the dog. Pharm Res. 1994 Mar;11(3):426-31.
• [32] Design of a potent and orally active nonpeptide platelet fibrinogen receptor (GPIIb/IIIa) antagonist. Bioorg Med Chem. 1994 Sep;2(9):897-908.
• [33] SC-49992--a potent and specific inhibitor of platelet aggregation. Thromb Res. 1994 Jun 1;74(5):523-35.
• [34] AlphaIIbbeta3 and its antagonism at the new millennium. Thromb Haemost. 2001 Jul;86(1):34-40.
• [35] Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM). J Clin Pharmacol. 2000 Oct;40(10):1129-40.
• [36] Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GpIIb/IIIa antagonist XV454. Thromb Haemost. 2003 Sep;90(3):549-54.